Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Leontien CM Kremer"'
Autor:
Esmée C, de Baat, Renée L, Mulder, Saro, Armenian, Elizabeth Am, Feijen, Heynric, Grotenhuis, Melissa M, Hudson, Annelies Mc, Mavinkurve-Groothuis, Leontien Cm, Kremer, Elvira C, van Dalen
Publikováno v:
Cochrane database of systematic reviews (Online), 2022(9):CD014638. John Wiley and Sons Ltd
BACKGROUND: This review is the third update of a previously published Cochrane Review. The original review, looking at all possible cardioprotective agents, was split and this part now focuses on dexrazoxane only. Anthracyclines are effective chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71377610311755696fcd76d412ffbb35
https://pure.amc.nl/en/publications/dexrazoxane-for-preventing-or-reducing-cardiotoxicity-in-adults-and-children-with-cancer-receiving-anthracyclines(4e30b0ff-bfd8-4483-8f4b-6350e9392b16).html
https://pure.amc.nl/en/publications/dexrazoxane-for-preventing-or-reducing-cardiotoxicity-in-adults-and-children-with-cancer-receiving-anthracyclines(4e30b0ff-bfd8-4483-8f4b-6350e9392b16).html
Autor:
Willemijn B Breunis, Lianne M Haveman, Bas Vaarwerk, Emilia C Owers, Rick R van Rijn, Henk van den Berg, Jérémie F Cohen, Leontien CM Kremer, Elvira C van Dalen, Johannes HM Merks
Publikováno v:
Cochrane database of systematic reviews (Online). John Wiley and Sons Ltd
ISSUE=8;TITLE=Cochrane database of systematic reviews
ISSUE=8;TITLE=Cochrane database of systematic reviews
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8363b50bdfeaa93376e0e274912f63a
https://doi.org/10.1002/14651858.cd012325
https://doi.org/10.1002/14651858.cd012325
Autor:
Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Daniel KL Cheuk, Huib N Caron, Leontien CM Kremer
Publikováno v:
Sieswerda, E, van Dalen, E C, Postma, A, Cheuk, D K L, Caron, H N & Kremer, L C M 2012, ' Cochrane Review : Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer ', Evidence-Based Child Health, vol. 7, no. 6, pp. 1857-1902 . https://doi.org/10.1002/ebch.1885
Background: Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunctio
Publikováno v:
The Cochrane Library
Cochrane Database Syst Rev
Cochrane Database Syst Rev
BACKGROUND: Despite the development of new treatment options, the prognosis of high‐risk neuroblastoma patients is still poor; more than half of patients experience disease recurrence. High‐dose chemotherapy and haematopoietic stem cell rescue (i
Autor:
Lianne M Haveman, Willemijn B Breunis, Elvira C van Dalen, Leontien CM Kremer, Uta Dirksen, Heribert Jürgens, Henk van den Berg, Johannes HM Merks
Publikováno v:
Cochrane Database of Systematic Reviews.
Publikováno v:
The Cochrane database of systematic reviews. (1)
One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of different types of childhood cancer should be based on the available evidence on both antitumour
Background One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of different types of childhood cancer should be based on the available evidence on both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b493a82117320f5674a42c2b95f901
https://doi.org/10.1002/14651858.cd006647.pub2
https://doi.org/10.1002/14651858.cd006647.pub2